Lymphoma presenting as Henoch–Schönlein purpura

Natalia Soerjadi1, Jonathan Zwi2,3 and Janak R. de Zoysa4,5

1Department of Medicine, North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand, 2LabPlus, Auckland, New Zealand, 3Department of Molecular Medicine and Pathology, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand, 4Department of Renal Medicine, North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand and 5Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand

Correspondence and offprint requests to: Janak R. de Zoysa; E-mail: janak.dezoysa@waitematadhb.govt.nz

Keywords: Henoch–Schönlein purpura; lymphoma; malignancy; vasculitis

Introduction

Henoch–Schönlein purpura (HSP) is a systemic vasculitis affecting the small blood vessels of the skin, the gastrointestinal tract and the kidneys. HSP typically affects children and is self-limiting. Less commonly it presents in adults. Several triggers for HSP have been recognized, including infections, medications and malignancy. This report describes a patient presenting with HSP who was found to have an underlying malignancy and highlights that in adults presenting with HSP a careful search for an underlying cause should be undertaken.

Case report

A 57-year-old man was referred from the Internal Medicine service at another hospital with presumed HSP. He presented with a 2-week history of fever, lethargy and night sweats, and 5 days of a widespread purpuric rash on the upper and lower extremities and new renal impairment, and a skin biopsy had shown a leukocytoclastic vasculitis. Apart from a history of malaria 20 years ago, for which he received prompt treatment, he was fit and healthy. A physical examination revealed an ill, febrile patient with palpable purpuric eruptions on all extremities (Figure 1). He was noted to have cervical lymphadenopathy and splenomegaly. His blood profile showed anaemia and thrombocytopenia (haemoglobin 99 g/L, platelet count 113 × 109/L, white cell count 10.5 × 109/L, neutrophils 8.0 × 109/L, monocytes 0.82 × 109/L, lymphocytes 1.29 × 109/L, haptoglobins 1.06 g/L). A CT body demonstrated normalization of the splenic size and no lymphadenopathy. He is now awaiting an autologous bone marrow transplant.

Discussion

HSP is a systemic vasculitis characterized by deposition of Immunoglobulin A (IgA) immune complexes in tissues. It is characterized by the clinical tetrad of palpable purpura, arthralgia ± arthritis, abdominal pain and renal disease. It is the most commonly seen vasculitis in childhood, the
majority of cases being reported in children and in this group the condition is typically self-limiting [1].

HSP is less common in adults and often does not present with the classic tetrad. If clinical features are present and IgA can be demonstrated on tissue biopsy, this establishes the diagnosis and allows a distinction to be made from other systemic vasculitides. A biopsy of the purpura typically demonstrates leucocytoclastic vasculitis, with inflammation most prominent in the post-capillary venules. As immunofluorescence in skin biopsy is often inconsistent [2], histology from other tissue is often sought. The renal biopsy changes may be mild with mesangial expansion or severe with a necrotizing crescentic glomerulonephritis with dominant expression of IgA; the changes are indistinguishable from those seen in IgA nephropathy.

The clinical diagnosis of HSP was made by the Internal Medicine service based on the presentation with palpable purpura, acute renal impairment and leucocytoclastic vasculitis on skin biopsy. As the patient had renal disease he was referred for further evaluation. However, when the patient was reviewed, there were a number of atypical features noted. Typically, there is neither coagulopathy, nor thrombocytopaenia, as was seen with our patient. The clinical features of lymphadenopathy and splenomegaly were also out of keeping with idiopathic HSP. This led to further evaluation demonstrating autoimmune haemolysis and lymphoma.

The aetiology of HSP is unknown; however, there are often precipitating triggers, such as an infective illness, a reaction to drugs or malignancy. Given the patient’s history of malaria and the finding of splenomegaly, we undertook a careful search for infective causes including a thick and thin film for malaria, and other infectious serology, all of which were all negative. Bacterial infections [3], viral infections [4], vaccinations [5] and parasites such as Plasmodium falciparum [6] have been described as potential triggers. A number of drugs have also been described as precipitating HSP [7]; however, our patient was not on any medications.

Malignancy has been reported as a potential trigger in patients with systemic vasculitis [8, 9], and specifically in adult-onset HSP [10–12] with a relative risk of 5.25 for malignancy found when compared with age-matched controls without HSP [13]. Myeloproliferative and lymphoproliferative malignancies are reported to be three to five times more common than solid malignancies when considering all types of vasculitis [9]. However, the prevalence of haematological malignancy is comparatively rare in adult-onset HSP, when compared with solid
malignancies and is associated with a poor prognosis [11]. Malignancy may be diagnosed either concurrently or after the diagnosis of HSP [9]. Importantly, when HSP occurs after a diagnosis of malignancy is known, it may signal that metastasis, or progression of the primary lesion have occurred [10, 11].

The pathogenetic mechanisms that lead malignancy to present as HSP or any vasculitis remain poorly understood [7]. It is believed that vasculitis behaves like a paraneoplastic syndrome and several mechanisms have been proposed, and these include (i) molecular mimicry between tumour neoantigens and endothelial cells, (ii) decreased immune complex clearance, (iii) increased antibody production, (iv) dysregulated antibody class switching from IgM to IgA, (v) reduced sialylation of the IgA hinge region and (vi) increased inflammatory cytokine release during neoplastic processes [14].

The renal prognosis for children presenting with HSP is generally favourable with 5–20% developing chronic kidney disease (CKD) [15, 16]. In adults, CKD is reported to occur in 35–69% although these represent a selected cohort of patients who underwent renal biopsy [17–20]. Little prospective randomized controlled trial evidence exists to guide therapy in patients with HSP although observational data exist [21]. Agents that have been used include, but are not limited to, pulse methylprednisolone, oral prednisone, cyclosporine, cyclophosphamide, azathioprine, mizoribine, plasma exchange, urokinase alone or in a combination [21]. In the case presented here, a diagnosis of angioimmunoblastic T-cell lymphoma was concurrently discovered in the absence of any other identifiable trigger of HSP resulting in a prompt initiation of chemotherapy and improvement of renal function.

In conclusion, we present a patient who presented with HSP but had atypical features, and who was found to have an underlying lymphoma.

Teaching points

(i) HSP classically presents with purpura, arthralgia, abdominal pain and renal impairment. In adults, there may be fewer clinical features and a tissue biopsy demonstrating that tissue deposition of IgA is required to confirm the diagnosis.

(ii) Renal disease is more common in adults and the renal prognosis for adults is worse.

(iii) A number of potential triggers have been identified in patients with HSP including infection, medications and malignancy. In adults presenting with HSP, a careful evaluation should be undertaken to determine a trigger, especially if atypical features are present. In patients for whom there is a known history of malignancy, the development of HSP should result in re-evaluation for a new metastatic lesion.

Acknowledgements. The authors would like to thank Dr Janeen Milner, General Practitioner, Auckland, New Zealand for reviewing and commenting on the manuscript. Consent has been obtained from the patient for discussion of his case.

Conflict of interest statement. None declared.

References

1. Eleftheriou E, Brogan PA. Vasculitis in children. Best Pract Res Clin Rheumatol 2009; 23: 305–323

2. Fallowfield M. Dermatopathology. Br J Dermatol 2005; 152: 13–28

3. Masuda M, Nakanishi K, Yoshizawa N et al. Group A streptococcal antigen in the glomeruli of children with Henoch–Schönlein nephritis. Am J Kidney Dis 2003; 41: 366–370

4. Lambert EM, Leibling A, Guasc E et al. Henoch–Schönlein purpura following a meningococcal vaccine. Pediatrics 2003; 112: e491

5. Chung JY, Wookkoo J, Kim SW. Henoch–Schönlein purpura after Varicella infection. Pediatr Infect Dis J 2005; 24: 288

6. Thapa R, Mallick D, Biswas B et al. Henoch–Schönlein purpura triggered by falciparum cerebral malaria. Clin Pediatr (Phila) 2010; 49: 699–701

7. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36: 130–147

8. Chakravarty E, Genovese MC. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 2003; 15: 35–43

9. Fain O, Hamidou M, Caobuc P et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 15: 1473–1480

10. Pertuiset E, Liéte F, Launay-Russ E et al. Adult Henoch–Schönlein Purpura associated with malignancy. Semin Arthritis Rheum 2000; 29: 360–367

11. Zurada JM, Ward KM, Grossman ME. Henoch–Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol 2006; 55: S65–S70

12. Mitsui H, Shibagaki N, Kawamura T et al. Henoch–Schönlein nephritis in adults and children. Italian J Nephrol 2002; 13: 1271–1278

13. Pankhurst T, Savage CO, Gordon C et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology 2004; 43: 1532–1535

14. Jithpratuck W, Elshenawy Y, Saleh H et al. The clinical implications of adult-onset Henoch–Schoenlein purpura. Clin Mol Allergy 2011; 9: 9

15. Koskimies O, Mir S, Rapola J et al. Henoch–Schönlein nephritis: Long-term prognosis of unselected patients. Arch Intern Med 1981; 56: 482–486

16. Goldstein AR, White RHR, Akuse R et al. Long-term follow-up of childhood Henoch–Schönlein nephritis. Lancet 1992; 339: 280–282

17. Fogazzi GB, Pasquali S, Moriggi M et al. Long-term outcome of Schönlein–Henoch nephritis in the adult. Clin Nephrol 1989; 31: 60–66

18. Coppo R, Mazzucco G, Cagnoli L et al. Long-term prognosis of Henoch–Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch–Schönlein purpura. Nephrol Dial Transplant 1997; 12: 2277–2283

19. Pillebout E, Theret E, Hill G et al. Henoch–Schönlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13: 1271–1278

20. Shrestha S, Sumingan N, Tan J et al. Henoch–Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM 2006; 99: 253–265

21. Davin JC. Henoch–Schönlein Purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol 2011; 6: 679–689

Received for publication: 24.5.12; Accepted in revised form: 16.8.12